Home › Funds › Encore Global Management, LP › CYTK
Encore Global Management, LP position in CYTK
Cytokinetics, Incorporated · Health Care
Encore Global Management, LP reported holding 12,731 shares of CYTK (Cytokinetics, Incorporated) in its Q3 2026 13F filing — a position valued at US$839K, representing 0.93% of its reported portfolio and ranking #36 among its reported holdings. Encore Global Management, LP has disclosed CYTK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Encore Global Management, LP's CYTK position evolved
Encore Global Management, LP first disclosed a stake in CYTK in Q1 2026 at 5,000 shares (US$330K). The position peaked in Q2 2026 at 12,731 shares, worth US$1.1M. Across 3 filings, Encore Global Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 12,731 shares valued at US$839K. Notable position changes include a 155% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 5.00K | $329.55K | New |
| Q2 2026 | 12.73K | $1.08M | Add |
| Q3 2026 | 12.73K | $839.10K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (Cytokinetics, Incorporated) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K sh · $59.63M · Q2 2026
More on Encore Global Management, LP
FAQ
How long has Encore Global Management, LP held CYTK?
Encore Global Management, LP has disclosed CYTK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Encore Global Management, LP's current position in CYTK?
As of Q3 2026, Encore Global Management, LP holds 12.73K shares of CYTK (Cytokinetics, Incorporated), valued at $839.10K, representing 0.93% of its reported portfolio and ranking #36.
Has Encore Global Management, LP been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Encore Global Management, LP held unchanged its position in CYTK. The position peaked in Q2 2026 at 12.73K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.